Sign In
Buy BIIB
$195.96
+7.13 (+3.78%)
At Close: Jun 03, 2026
These Are the 5 Worst-Performing Stocks in the Nasdaq-100 With 2024 Almost Over
07:30am, Tuesday, 26'th Nov 2024
The Nasdaq-100 index tracks the largest 100 non-financial companies on the Nasdaq stock exchange. Although it's not a part of the U.S. stock market's big three indexes ( S&P 500 , Nasdaq Composite, a
Biogen Gains Momentum With Positive Lupus Drug Results, Analyst Sees Modest Valuation Upside
01:32pm, Wednesday, 20'th Nov 2024
On Tuesday, UCB SA UCBJY UCBJF and Biogen Inc. BIIB presented detailed results from the Phase 3 PHOENYCS GO study evaluating dapirolizumab pegol (DZP) for systemic lupus erythematosus.
BRUSSELS, Belgium and CAMBRIDGE, Mass., Nov. 19, 2024 (GLOBE NEWSWIRE) -- UCB (Euronext Brussels: UCB) and Biogen Inc. (NASDAQ: BIIB) today presented detailed results from the Phase 3 PHOENYCS GO stud
Biogen's Outlook Dims As Analyst Projects Flat Revenue Until 2026
01:18pm, Monday, 18'th Nov 2024
Needham downgraded Biogen Inc BIIB, citing limited catalysts for the company over the next year.
Samsung Bioepis and Biogen Receive European Commission (EC) Approval for Aflibercept Biosimilar, OPUVIZ™
07:00am, Monday, 18'th Nov 2024
INCHEON, South Korea and CAMBRIDGE, Mass., Nov. 18, 2024 (GLOBE NEWSWIRE) -- Samsung Bioepis Co., Ltd. and Biogen Inc. (Nasdaq: BIIB) today announced that the European Commission (EC) has approved OPU
Biogen Partner Eisai Gets Positive CHMP Nod for Leqembi in Europe
10:05am, Friday, 15'th Nov 2024
The CHMP renders a positive opinion recommending approval for BIIB and Eisai's Leqembi for treating early Alzheimer's disease.
Biogen's stock rises after E.U. regulator reverses negative view of Alzheimer's drug
01:21pm, Thursday, 14'th Nov 2024
Biogen's stock rose 1% Thursday, after Europe's pharmaceutical regulator issued a positive opinion on the Alzheimer's disease drug that the company developed with Japanese partner Eisai — reversing
Eisai Receives Positive Opinion from the CHMP in the European Union for Lecanemab in Early Alzheimer's Disease
11:23am, Thursday, 14'th Nov 2024
TOKYO and CAMBRIDGE, Mass., Nov. 14, 2024 (GLOBE NEWSWIRE) -- Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Mas
EU drugs regulator recommends Alzheimer's drug from Eisai-Biogen
11:17am, Thursday, 14'th Nov 2024
The European Union's drugs regulator on Thursday said it recommends approval of Eisai and Biogen's Leqembi in patients with early Alzheimer's disease, months after the agency first rejected the treatm
Biogen initiated with a Neutral at Citi
04:13pm, Wednesday, 13'th Nov 2024
Citi analyst Geoff Meacham initiated coverage of Biogen with a Neutral rating and $190 price target. The company's strategy to offset core franchise erosion has been to develop assets with significant
Here's Why Biogen Inc. (BIIB) is a Strong Value Stock
10:46am, Tuesday, 12'th Nov 2024
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
BIIB vs. MYGN: Which Stock Is the Better Value Option?
12:45pm, Wednesday, 06'th Nov 2024
Investors with an interest in Medical - Biomedical and Genetics stocks have likely encountered both Biogen Inc. (BIIB) and Myriad Genetics (MYGN). But which of these two stocks offers value investors
Are Investors Undervaluing Biogen (BIIB) Right Now?
10:45am, Tuesday, 05'th Nov 2024
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest
Biogen (BIIB) Loses -6.4% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
10:35am, Monday, 04'th Nov 2024
Biogen (BIIB) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates co
Biogen Q3 Earnings Review: Why I Remain Optimistic Despite Difficult Quarter
05:42pm, Thursday, 31'st Oct 2024
Biogen reported its Q3 earnings yesterday, October 30. Revenue of $2.5bn was reported and non-GAAP EPS of $4.08. Growth was generally flat or declining for many key assets, with the performance of AD
